Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas
Status:
Completed
Trial end date:
2020-02-20
Target enrollment:
Participant gender:
Summary
Multicenter prospective open-label non-randomised phase I/II study in patients with relapsed
or refractory CD20-positive aggressive lymphomas
Phase I:
Dose escalation of methotrexate and cytarabine (days 1, 8 and 15 of each 28-day cycle) in a 3
+ 3 design with fixed doses of lenalidomide (days 1 - 21) and rituximab (day 1), maximum 6
cycles
Phase II:
Treatment of 20 patients at maximum tolerated doses of phase I